CO2019005955A2 - Preparación farmacéutica y método para su fabricación - Google Patents
Preparación farmacéutica y método para su fabricaciónInfo
- Publication number
- CO2019005955A2 CO2019005955A2 CONC2019/0005955A CO2019005955A CO2019005955A2 CO 2019005955 A2 CO2019005955 A2 CO 2019005955A2 CO 2019005955 A CO2019005955 A CO 2019005955A CO 2019005955 A2 CO2019005955 A2 CO 2019005955A2
- Authority
- CO
- Colombia
- Prior art keywords
- layer
- matrix material
- preparation
- pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una preparación farmacéutica sólida. La presente invención se refiere a una preparación (10) farmacéutica que comprende una primera composición farmacéutica que tiene un material de matriz e ingredientes farmacéuticamente activos que se distribuyen en el material de matriz, en la que la primera composición farmacéutica comprende Praziquantel, Pirantel y Febantel como ingredientes farmacéuticos activos, en la que la preparación (10) comprende una segunda composición farmacéutica que tiene un material de matriz y al menos una de avermectinas y milbemicinas tal como Moxidectina como ingrediente farmacéuticamente activo que se distribuye en el material de matriz, en la que la preparación (10) se proporciona en una estructura de múltiples capas de manera tal que la primera composición se proporciona en una primera capa (12) y la segunda composición se proporciona en una segunda capa (14), en la que la primera capa (12) y la segunda capa (14) se separan mediante una capa (16) barrera que se proporciona entre la primera capa (12) y la segunda capa (14).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16203308 | 2016-12-09 | ||
| PCT/EP2017/081049 WO2018104150A1 (en) | 2016-12-09 | 2017-11-30 | Pharmaceutical preparation and method for its manufacture |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019005955A2 true CO2019005955A2 (es) | 2019-06-19 |
Family
ID=57544274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0005955A CO2019005955A2 (es) | 2016-12-09 | 2019-06-07 | Preparación farmacéutica y método para su fabricación |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11382865B2 (es) |
| EP (1) | EP3551173A1 (es) |
| JP (1) | JP2020500898A (es) |
| KR (1) | KR20190093571A (es) |
| CN (1) | CN110022862B (es) |
| AU (1) | AU2017370975A1 (es) |
| BR (1) | BR112019011502A2 (es) |
| CA (1) | CA3046275A1 (es) |
| CL (1) | CL2019001555A1 (es) |
| CO (1) | CO2019005955A2 (es) |
| DO (1) | DOP2019000157A (es) |
| IL (1) | IL266938A (es) |
| MX (1) | MX2019006742A (es) |
| PH (1) | PH12019501249A1 (es) |
| RU (1) | RU2764849C2 (es) |
| WO (1) | WO2018104150A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021006821A2 (pt) * | 2018-10-12 | 2021-07-13 | Hovione Scientia Limited | método de tratamento de inflamação e patologias oftálmicas, dispersão sólida, formulação farmacêutica, método de matar ácaros e kit |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4999226A (en) | 1988-06-01 | 1991-03-12 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination |
| US5030622A (en) | 1989-06-02 | 1991-07-09 | Merck & Co., Inc. | Avermectin derivatives |
| IT1264517B1 (it) | 1993-05-31 | 1996-09-24 | Ekita Investments Nv | Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati |
| DE60118132T2 (de) | 2000-10-10 | 2006-10-19 | Wyeth | Anthelmintika |
| US6893652B2 (en) * | 2001-08-27 | 2005-05-17 | Wyeth | Endoparasiticidal gel composition |
| IN191024B (es) | 2001-09-25 | 2003-09-13 | J B Chemicals And Pharmaceutic | |
| US20040151759A1 (en) * | 2002-08-16 | 2004-08-05 | Douglas Cleverly | Non-animal product containing veterinary formulations |
| TWI366442B (en) | 2003-07-30 | 2012-06-21 | Novartis Ag | Palatable ductile chewable veterinary composition |
| US7396819B2 (en) | 2003-08-08 | 2008-07-08 | Virbac Corporation | Anthelmintic formulations |
| WO2005084688A1 (fr) | 2004-03-04 | 2005-09-15 | Yuwan Wang | Poudre injectable contenant un vermifuge |
| US20060024368A1 (en) | 2004-07-30 | 2006-02-02 | Reza Fassihi | Compressed composite delivery system for release-rate modulation of bioactives |
| WO2006036624A2 (en) | 2004-09-24 | 2006-04-06 | The Hartz Mountain Corporation | Lipid stabilized formulations |
| US7348027B2 (en) | 2005-04-08 | 2008-03-25 | Bayer Healthcare Llc | Taste masked veterinary formulation |
| NZ580357A (en) * | 2007-05-07 | 2011-06-30 | Jurox Pty Ltd | Chewable gelatinised protein dosage form and process |
| US20080293645A1 (en) | 2007-05-25 | 2008-11-27 | Schneider Lawrence F | Antiparasitic combination and method for treating domestic animals |
| BR112014013371B1 (pt) | 2011-12-02 | 2020-04-07 | Merial Ltd | formulações de moxidectina injetável de ação prolongada e novas formas de cristal de moxidectina |
| HU231017B1 (hu) | 2012-05-08 | 2019-11-28 | LAVET Gyógyszeripari Kft. | Praziquantel tartalmú ízfedett formulációk |
| MX2015007640A (es) | 2012-12-19 | 2015-09-23 | Bayer Animal Health Gmbh | Comprimidos que tienen aceptacion mejorada y buena estabilidad durante el almacenamiento. |
| WO2015071668A1 (en) * | 2013-11-14 | 2015-05-21 | Cipla Limited | Pharmaceutical compositions |
| WO2018065826A1 (en) * | 2016-10-06 | 2018-04-12 | Sucampo Ag | Multilayer beads for pharmaceutical use |
-
2017
- 2017-11-30 MX MX2019006742A patent/MX2019006742A/es unknown
- 2017-11-30 BR BR112019011502-1A patent/BR112019011502A2/pt active Search and Examination
- 2017-11-30 WO PCT/EP2017/081049 patent/WO2018104150A1/en active Application Filing
- 2017-11-30 RU RU2019121235A patent/RU2764849C2/ru active
- 2017-11-30 EP EP17808868.8A patent/EP3551173A1/en not_active Withdrawn
- 2017-11-30 JP JP2019530446A patent/JP2020500898A/ja active Pending
- 2017-11-30 US US16/467,922 patent/US11382865B2/en active Active
- 2017-11-30 KR KR1020197016071A patent/KR20190093571A/ko not_active Application Discontinuation
- 2017-11-30 CA CA3046275A patent/CA3046275A1/en active Pending
- 2017-11-30 CN CN201780075878.3A patent/CN110022862B/zh active Active
- 2017-11-30 AU AU2017370975A patent/AU2017370975A1/en not_active Abandoned
-
2019
- 2019-05-28 IL IL266938A patent/IL266938A/en unknown
- 2019-06-04 PH PH12019501249A patent/PH12019501249A1/en unknown
- 2019-06-06 CL CL2019001555A patent/CL2019001555A1/es unknown
- 2019-06-07 CO CONC2019/0005955A patent/CO2019005955A2/es unknown
- 2019-06-07 DO DO2019000157A patent/DOP2019000157A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL266938A (en) | 2019-07-31 |
| CN110022862B (zh) | 2022-05-24 |
| EP3551173A1 (en) | 2019-10-16 |
| CA3046275A1 (en) | 2018-06-14 |
| WO2018104150A1 (en) | 2018-06-14 |
| US20200069591A1 (en) | 2020-03-05 |
| JP2020500898A (ja) | 2020-01-16 |
| MX2019006742A (es) | 2019-09-05 |
| US11382865B2 (en) | 2022-07-12 |
| AU2017370975A1 (en) | 2019-05-30 |
| RU2019121235A3 (es) | 2021-02-16 |
| PH12019501249A1 (en) | 2019-12-02 |
| BR112019011502A2 (pt) | 2019-11-05 |
| CN110022862A (zh) | 2019-07-16 |
| RU2764849C2 (ru) | 2022-01-21 |
| DOP2019000157A (es) | 2019-07-15 |
| KR20190093571A (ko) | 2019-08-09 |
| RU2019121235A (ru) | 2021-01-12 |
| CL2019001555A1 (es) | 2019-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017012362A2 (es) | Formas de dosificación sólida que comprenden palbociclib, un ácido hidrosoluble y un portador farmacéuticamente aceptable y métodos para su produccion y uso | |
| CO6470799A2 (es) | Composición farmacéutica oral auto-microemulsificante de un farmaco hidrofílico y método de preparación de ésta | |
| CL2018002718A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| BRPI0513909A (pt) | comprimido farmacêutico de camada múltipla para a liberação controlada de ingredientes ativos com solubilidade altamente dependente do ph | |
| CL2020000747A1 (es) | Formulaciones de niraparib. | |
| AR116999A1 (es) | Conjugados citostáticos con ligandos de integrina | |
| AR076411A1 (es) | Suplemento de alimentacion granulado | |
| CO6710926A2 (es) | Compuestos de n-heteroarilo | |
| GT200900062A (es) | Nuevos compuestos de diosmetina, un proceso para su preparacion y las composiciones farmaceuticas que los contienen | |
| PE20150721A1 (es) | Composicion farmaceutica que comprende gemigliptina y metformina, y metodo para su preparacion | |
| BR112022000982A2 (pt) | Forma de dosagem veterinária mastigável macia | |
| CO2019011547A2 (es) | Compuesto sólido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol | |
| CL2013003585A1 (es) | Procedimiento para preparar una tableta de caldo que tiene dos o más capas, el cual consiste en las etapas de (a) formar una primera capa de la tableta, (b) formar una segunda capa de la tableta y (c) comprimir las dos capas para formar la tableta. | |
| CO2018014318A2 (es) | Artículo absorbente que tiene un sistema de sujeción mejorado y un método para fabricar tal artículo absorbente | |
| CL2012003341A1 (es) | Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades. | |
| CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
| CO7151497A2 (es) | Composiciones parasiticidas que comprenden derivados de benzimidazol, métodos y usos de los mismos | |
| CO2018004665A2 (es) | Compuestos oxadiazoespíricos | |
| CO2019005955A2 (es) | Preparación farmacéutica y método para su fabricación | |
| CO2017013305A2 (es) | Composiciones farmacéuticas sólidas de dos capas para el tratamiento de vhc | |
| AR097202A1 (es) | Composiciones farmacéuticas de ranolazina y dronedarona, procedimiento para elaborar tableta bicapa | |
| BR112017016042A2 (pt) | cápsula compósita, e, método para preparar uma cápsula compósita | |
| ECSP18008411A (es) | Composiciones farmacéuticas sólidas para el tratamiento del vhc | |
| BR112021024026A2 (pt) | Método para a produção de uma forma de dosagem farmacêutica sólida ou semissólida, forma de dosagem farmacêutica sólida ou semissólida e forma de dosagem sólida ou semissólida | |
| CO2017000354A2 (es) | Desmopresina estabilizada |